CN113527507A - 靶向cd22的嵌合抗原受体及其制法和应用 - Google Patents

靶向cd22的嵌合抗原受体及其制法和应用 Download PDF

Info

Publication number
CN113527507A
CN113527507A CN202010301357.9A CN202010301357A CN113527507A CN 113527507 A CN113527507 A CN 113527507A CN 202010301357 A CN202010301357 A CN 202010301357A CN 113527507 A CN113527507 A CN 113527507A
Authority
CN
China
Prior art keywords
car
ser
gly
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010301357.9A
Other languages
English (en)
Chinese (zh)
Inventor
姚意弘
朱琳
李延峰
魏雨恬
姚昕
朱恃贵
黄家琪
张丽
刘必佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Abelzeta Ltd
Original Assignee
Wuxi Cellular Biopharmaceutical Group Ltd
Shanghai Cellular Biopharmaceutical Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Cellular Biopharmaceutical Group Ltd, Shanghai Cellular Biopharmaceutical Group Ltd filed Critical Wuxi Cellular Biopharmaceutical Group Ltd
Priority to CN202010301357.9A priority Critical patent/CN113527507A/zh
Priority to PCT/CN2021/085062 priority patent/WO2021208750A1/zh
Priority to US17/918,414 priority patent/US20230144447A1/en
Priority to KR1020227039524A priority patent/KR20220167330A/ko
Priority to JP2022562556A priority patent/JP2023521218A/ja
Priority to AU2021255412A priority patent/AU2021255412A1/en
Priority to EP21788934.4A priority patent/EP4151653A4/en
Priority to CA3179551A priority patent/CA3179551A1/en
Publication of CN113527507A publication Critical patent/CN113527507A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202010301357.9A 2020-04-16 2020-04-16 靶向cd22的嵌合抗原受体及其制法和应用 Pending CN113527507A (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202010301357.9A CN113527507A (zh) 2020-04-16 2020-04-16 靶向cd22的嵌合抗原受体及其制法和应用
PCT/CN2021/085062 WO2021208750A1 (zh) 2020-04-16 2021-04-01 靶向cd22的嵌合抗原受体及其制法和应用
US17/918,414 US20230144447A1 (en) 2020-04-16 2021-04-01 Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof
KR1020227039524A KR20220167330A (ko) 2020-04-16 2021-04-01 Cd22-표적화된 키메라 항원 수용체, 그의 제조 방법 및 그의 적용
JP2022562556A JP2023521218A (ja) 2020-04-16 2021-04-01 Ｃｄ２２標的キメラ抗原受容体、その調製方法、及びその適用
AU2021255412A AU2021255412A1 (en) 2020-04-16 2021-04-01 CD22-targeted chimeric antigen receptor, preparation method therefor and application thereof
EP21788934.4A EP4151653A4 (en) 2020-04-16 2021-04-01 Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof
CA3179551A CA3179551A1 (en) 2020-04-16 2021-04-01 Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010301357.9A CN113527507A (zh) 2020-04-16 2020-04-16 靶向cd22的嵌合抗原受体及其制法和应用

Publications (1)

Publication Number Publication Date
CN113527507A true CN113527507A (zh) 2021-10-22

Family

ID=78083511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010301357.9A Pending CN113527507A (zh) 2020-04-16 2020-04-16 靶向cd22的嵌合抗原受体及其制法和应用

Country Status (8)

Country Link
US (1) US20230144447A1 (https=)
EP (1) EP4151653A4 (https=)
JP (1) JP2023521218A (https=)
KR (1) KR20220167330A (https=)
CN (1) CN113527507A (https=)
AU (1) AU2021255412A1 (https=)
CA (1) CA3179551A1 (https=)
WO (1) WO2021208750A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116462770B (zh) * 2023-04-18 2024-03-08 科弈(浙江)药业科技有限公司 Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101626782A (zh) * 2006-12-01 2010-01-13 梅达雷克斯公司 结合cd22的人抗体及其用途
CN108137703A (zh) * 2015-10-15 2018-06-08 美国卫生和人力服务部 抗cd30嵌合抗原受体
CN108715859A (zh) * 2018-05-31 2018-10-30 中国医学科学院血液病医院（血液学研究所） 靶向cd22的嵌合抗原受体及其应用
CN110372796A (zh) * 2018-04-12 2019-10-25 西比曼生物科技（香港）有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2019213434A1 (en) * 2018-05-02 2019-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
CN111601823A (zh) * 2017-11-07 2020-08-28 德克萨斯大学体系董事会 用car-t或car-nk细胞在癌症治疗中靶向lilrb4

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
EP2032606B1 (en) 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
MX361533B (es) 2012-04-26 2018-12-07 Bioatla Llc Anticuerpos anti-cd22.
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
BR112019006781A2 (pt) * 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
CN107964549B (zh) * 2016-10-20 2020-12-08 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
AU2018246377B2 (en) * 2017-03-31 2025-01-30 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
US10543263B2 (en) * 2017-10-16 2020-01-28 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD22 immunotherapy
CN109836495A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd22的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
US12036242B2 (en) * 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101626782A (zh) * 2006-12-01 2010-01-13 梅达雷克斯公司 结合cd22的人抗体及其用途
CN108137703A (zh) * 2015-10-15 2018-06-08 美国卫生和人力服务部 抗cd30嵌合抗原受体
CN111601823A (zh) * 2017-11-07 2020-08-28 德克萨斯大学体系董事会 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
CN110372796A (zh) * 2018-04-12 2019-10-25 西比曼生物科技（香港）有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2019213434A1 (en) * 2018-05-02 2019-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
CN108715859A (zh) * 2018-05-31 2018-10-30 中国医学科学院血液病医院（血液学研究所） 靶向cd22的嵌合抗原受体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NIRALI N. SHAH等: "CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial" *

Also Published As

Publication number Publication date
EP4151653A4 (en) 2024-05-08
KR20220167330A (ko) 2022-12-20
AU2021255412A1 (en) 2022-11-17
EP4151653A1 (en) 2023-03-22
WO2021208750A1 (zh) 2021-10-21
US20230144447A1 (en) 2023-05-11
CA3179551A1 (en) 2021-10-21
JP2023521218A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
JP7299294B2 (ja) Ｂｃｍａを標的とするキメラ抗原受容体およびその製造方法と使用
CN110760007B (zh) Cd7-car-t细胞及其制备和应用
CN110950953B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN113784732A (zh) 靶向bcma的工程化免疫细胞及其用途
CN109575143B (zh) 双特异性cd20-cd19-car及其应用
CN113784733A (zh) 靶向bcma的工程化免疫细胞及其用途
CN113087806B (zh) 靶向多种肿瘤的新型car-t细胞及其制备和方法
CN112778427B (zh) 双特异性cs1-bcma car-t细胞及其应用
CN113402612A (zh) 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN113621582B (zh) 联合表达CCR2b的工程化免疫细胞及其制备和应用
CN109897114B (zh) 具有自杀基因开关的靶向cd47的工程化免疫细胞
CN113755448A (zh) 联合表达CCR2b和CD40L的工程化免疫细胞及其制备和应用
CN113651893A (zh) 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
CN114763388B (zh) 靶向b7-h3的car-t细胞及其在急性髓系白血病治疗中的应用
CN114685684A (zh) MUC1-Tn嵌合抗原受体修饰的Vγ9Vδ2T细胞及其应用
CN116462770B (zh) Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用
CN113527507A (zh) 靶向cd22的嵌合抗原受体及其制法和应用
CN114853893A (zh) 一种靶向gpc3嵌合抗原受体t细胞及其应用
CN114685683A (zh) 靶向gd2的car-t细胞及其制备和应用
HK40077704A (en) Targeted gpc3 chimeric antigen receptor t cell and application thereof
HK40087789A (en) Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof
CN118085102A (zh) 一种基于cd27分子的car组件设计与应用
CN115572715A (zh) 一种靶向folr1和her2双打靶点car t的制备及应用
HK40062446A (en) Engineered immune cell targeting bcma and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230526

Address after: 201210 building 3, Faraday Road, China (Shanghai) free trade pilot area, Pudong New Area, Shanghai, China (3)

Applicant after: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd.

Address before: 201210 building 3, Faraday Road, China (Shanghai) free trade pilot area, Pudong New Area, Shanghai, China (3)

Applicant before: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd.

Applicant before: WUXI CELLULAR BIOPHARMACEUTICAL Group Ltd.